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Background: Indacaterol is a novel, inhaled, once-daily ultra long-acting b2-agonist (ultra-
LABA) for the treatment of COPD. This study investigated the effect of indacaterol on exercise
endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-
to-severe COPD.
Methods: In this double-blind, placebo-controlled, two-period crossover study (3-week treat-
ment, 3-week washout between treatments), patients were randomized to receive indacaterol
300 mg once-daily or matching placebo. The primary efficacy variable was exercise endurance
time after 3 weeks of treatment, measured through constant-load cycle ergometry testing per-
formed at 75% of the peak work rate in a screening incremental exercise test.
Results: Of 90 patients randomized (mean age: 62.8 years; post-bronchodilator FEV1: 61.2%
predicted and FEV1/FVC: 51.6%), 74 completed the study. Pre-treatment exercise tolerance
averaged 459 s. Improvement in exercise endurance time was higher with indacaterol
300 mg than with placebo both after the first dose (treatment difference: 101 s; p < 0.001)
and after 3 weeks (treatment difference: 111 s; pZ 0.011). In addition, indacaterol increased
end-exercise inspiratory capacity (IC) versus placebo after 3 weeks (0.28 L, pZ 0.002). Signif-
icant improvements were also observed in resting IC (0.17 L, p Z 0.001), FEV1 (0.25 L,
p < 0.001) and FVC (0.26 L, p < 0.001) with indacaterol compared with placebo at 75 min
post-dose after 3 weeks.2 778 9479; fax: þ1 9737818265.
novartis.com (B. Kramer).
exercise-based, and lung evaluation 1.
1 Elsevier Ltd. All rights reserved.
Indacaterol and exercise endurance 1031Conclusion: In conclusion, indacaterol treatment improved the ability of patients with COPD to
exercise. In addition, the improvements observed in resting and end-exercise IC indicate
reductions in lung hyperinflation after 3 weeks treatment (ClinicalTrials.gov registration
number: NCT00620022).
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
disease, characterized by a progressive decline in lung
function, with both pulmonary and extra-pulmonary
effects.1 One of the major consequences of COPD is expi-
ratory flow limitation, leading to lung hyperinflation.
Dynamic hyperinflation occurs during periods of increased
ventilatory demand, particularly during exercise. Lung
hyperinflation in turn reduces inspiratory capacity (IC),
a lung volume measure that correlates with dyspnea and
exercise tolerance in patients with moderate-to-severe
COPD.2,3 Limitation in exercise capacity represents an
important feature of COPD, and is one of the main factors
to negatively impact patients’ quality of life.4
In clinical practice, bronchodilators are recommended
for symptomatic relief in COPD patients with all stages of
severity. Bronchodilators, including long-acting b2-agonists
(LABAs), have been shown to increase IC both at rest and
during exercise in patients with COPD by reducing lung
hyperinflation, with a resultant improvement in exercise
capacity.5,6 Indacaterol is a novel, inhaled ultra-LABA
providing 24-h bronchodilation with once-daily dosing in
patients with COPD.7e10 Indacaterol has been approved in
more than 50 countries worldwide, including throughout
the European Union, for maintenance treatment of COPD at
the doses of 150 mg and 300 mg once-daily. This study was
designed to examine the impact of indacaterol 300 mg once-
daily on exercise endurance time and lung hyperinflation in
patients with moderate-to-severe COPD.
Methods
This was a phase III, randomized, multi-center, multina-
tional, double-blind, placebo-controlled, two-period
crossover study conducted at specialized respiratory care
centers (ClinicalTrials.gov registration number:
NCT00620022).11 Institutional review board or independent
ethics committee approval was obtained at each partici-
pating study center. The study was conducted in accor-
dance with the Declaration of Helsinki (1989) and local
applicable laws and regulations. All patients provided
written informed consent prior to their participation in the
study.
Patients
Male and female patients aged 40 years, with a clinical
diagnosis of moderate-to-severe COPD (according to GOLD
2005 guideline),12 marked by a post-bronchodilator forced
expiratory volume in 1 s (FEV1) <80% and 30% of the
predicted normal value13 (i.e., Stage II or III) and a post-bronchodilator FEV1/forced vital capacity (FVC) <70%, and
a smoking history of at least 20 pack-years were eligible for
enrollment in the study. Patients were excluded if they had
been hospitalized for a COPD exacerbation in the 6 weeks
prior to screening or during the run-in period, had experi-
enced a respiratory tract infection in the 6 weeks prior to
screening, experienced oxygen desaturation <80% during
cycle exercise, or had contraindications to cardiopulmo-
nary exercise testing including electrolyte abnormalities.
Patients with concomitant pulmonary disease, type I dia-
betes or uncontrolled type II diabetes or with a history of
asthma were also excluded, as were patients with
a maximum work rate <20 W at screening.
Study design
The study comprised a pre-screening visit, a 14-day
screening period, and two 3-week treatment periods. At
the baseline visit, eligible patients were randomized
equally to one of two treatment sequences to receive
either indacaterol 300 mg once-daily in the first period
followed by placebo in the second period, or to receive
placebo in the first period followed by indacaterol in the
second, each via a single-dose dry powder inhaler (SDDPI).
Each treatment period was separated by a washout period
of 3 weeks. Patients, investigators, clinic staff performing
assessments, data analysts, and the sponsor’s trial team
were blinded to treatment from the time of randomization
until database lock.
Concomitant treatment
Daily inhaled corticosteroid (ICS) monotherapy was
allowed, if the patient was using ICS on entry to the study,
at a dose and regimen to remain stable throughout the
study. Patients were not allowed to use the following
medications: long- or short-acting anticholinergics,
theophyllines or xanthine derivatives, parenteral or oral
corticosteroids, and LABAs or short-acting b2-agonists other
than those prescribed in the study. Patients using fixed
combinations of ICS and LABA on study entry were switched
to the equivalent ICS monotherapy at a dose and regimen
maintained throughout the study. Salbutamol was available
as a rescue medication throughout the study.
Assessments
The primary efficacy variable, exercise endurance time (in
seconds) was measured through constant-load cycle ergo-
metry testing at 75% of the maximum work rate (Wmax)
after 3 weeks of treatment. Period baseline for the exercise
endurance test was defined as the pre-treatment exercise
1032 D.E. O’Donnell et al.time (in seconds) measured at a visit that took place 4e9
days prior to the scheduled start of each treatment period.
Cardiopulmonary exercise testing was performed using
incremental and constant-load cycle ergometry.14 The
cycle ergometer exercise test procedures commenced with
a period of quiet breathing for at least 3 min, followed by
pre-exercise resting measurement over a 30 s interval
before commencing pedaling. At screening, patients
underwent an incremental cycle ergometry test to deter-
mine their Wmax (defined as the greatest work rate that was
maintained for 30 s at 50e70 rpm), with initial unloaded
pedaling for 3 min followed by an immediate increase in
work rate to 10 W and then by further increments of 10 W
every minute until symptom limitation. For each constant-
load cycle ergometer test, patients commenced 3 min
unloaded pedaling at 50e70 rpm, followed by an immediate
increase in work rate to 75% Wmax, with pedaling to
continue until symptom limitation. The exercise endurance
time was recorded as the duration of loaded pedaling, i.e.,
from the commencement of loaded pedaling to the
symptom-limited endpoint where the patient indicated
that they needed to stop exercise or could no longer
maintain the required pedaling rate. Secondary efficacy
variables included exercise endurance on Day 1, end-
exercise IC and Borg CR10 scale outcomes on Day 1 and
after 3 weeks of treatment. End-exercise IC measurements
were collected from one maneuver performed immediately
after the patient indicated that they could no longer
continue loaded pedaling, preferably prior to lowering the
load. The Borg CR10 scale was used to measure the level of
dyspnea and leg discomfort during exercise, with assess-
ments performed pre-exercise, and immediately upon
completion of exercise.
Additional secondary efficacy variables included resting
spirometry variables (IC, FEV1 and FVC) at 75 min post-
dose on Day 1 and at 60 min predose and 75 min post-
dose (before commencing the exercise test) after 3 weeks
of treatment. Spirometry was conducted according to
American Thoracic Society (ATS)/European Respiratory
Society (ERS) standards.15 Resting spirometry variables
were determined from two separate sets of spirometer
maneuvers e a set of IC maneuvers (with the mean value
from three acceptable maneuvers recorded), and a set of
forced expiratory maneuvers (for FEV1 and FVC, with the
highest values from three acceptable maneuvers
recorded).
Patients’ activity was assessed using a 120-h actigraphy
device (Bodymedia SenseWear Armband device) worn for
the final 5 days in each treatment period (the device was to
be worn continually for this 5-day period, except that it was
to be removed while bathing). Patient diaries were
provided to patients for recording their daily clinical
symptoms (overall, cough, wheeze, sputum and breath-
lessness, each assessed on a scale of 0e3) and rescue
medication usage throughout the study. The mean total
symptom scores and individual symptom scores for the
patients were calculated over 3 weeks.
Safety assessments included recording of adverse events
(AEs) and serious AEs (SAEs), along with evaluation of their
severity, duration, and relationship to study drug. Other
safety assessments included regular monitoring of vital
signs, electrocardiograms (ECGs) and other standardclinical laboratory evaluations such as hematology, blood
chemistry and urinalysis.
Statistical analysis
It was estimated that 70 patients were needed to complete
the study, assuming a difference of 120 s between indaca-
terol and placebo in constant work rate exercise endurance
time based on data from three studies,2,5,16 with a standard
deviation of 305.2 s (based on data from a previous for-
moterol study5), a two-sided significance level of 5%, and
a power of 90%. Allowing for a 15% dropout rate, it was
calculated that 83 patients had to be randomized.
The efficacy variables were analyzed on the modified
intent-to-treat (mITT) population, which included all
randomized patients who received at least one dose of
study drug. Missing values were not imputed; patients with
efficacy measurements from only one treatment period
were considered in the population for calculation of
treatment means but were excluded for treatment
contrasts. All safety analyses were performed on the safety
population, which included all patients who received at
least one dose of study drug.
The primary efficacy variable was analyzed using
a mixed model, with treatment, period baseline exercise
endurance time, and period as fixed effects, and patient as
random effect. The least squares mean (LSM) adjusted
treatment difference for indacaterol 300 mg versus placebo
was estimated along with the associated 95% confidence
interval and two-sided p-value. Secondary efficacy vari-
ables were analyzed using similar mixed models as used for
the primary variable. AE and SAE data, laboratory data,
electrocardiogram (ECG) results, and measurements of
vital signs were summarized descriptively by treatment
group.
Results
This study was conducted at 18 centers in 6 countries
(Spain, Belgium, Italy, Denmark, Canada and USA). The first
patient was enrolled in April, 2008; the last patient
completed the study in January, 2009.
Patient disposition, demographics, and baseline
characteristics
Of 114 patients screened, 90 were randomized and 74
(82.2%) completed the study. One randomized patient
withdrew from the study prior to exposure to study drug. Of
the 15 patients that withdrew after exposure to study drug,
14 withdrew due to adverse events; one patient withdrew
consent.
The baseline demographics and clinical characteristics
of all exposed patients are shown in Table 1. The majority
of patients were male with a mean age of 63 years; 88
(98.9%) patients were Caucasian. The mean duration of
COPD was 6.3 years, with the largest proportion of patients
(76.4%) determined to have COPD of moderate severity. All
calculations to determine the severity of COPD in patients
at screening were performed at study centers. After data-
base lock, COPD severity was derived using a standardized
Table 1 Patient demographics and baseline characteristics.
Characteristics Total (N Z 89)
Age (years) 62.8 (8.20)
Sex, n (%)
Male 62 (69.7)
Female 27 (30.3)
BMI (kg/m2) 27.5 (4.14)
Duration of COPD (years) 6.3 (5.87)
COPD severity (GOLD 2005), n (%)
Mild 4 (4.5)
Moderate 68 (76.4)
Severe 17 (19.1)
Pre-bronchodilator FEV1 (L) 1.52 (0.470)
Post-bronchodilator FEV1 (L) 1.71 (0.492)
Post-bronchodilator FEV1 (% predicted) 61.2 (12.36)
Range 32.3e84.5
Post-bronchodilator FEV1/FVC (%) 51.6 (10.51)
FEV1 reversibility (% increase) 13.1 (10.98)
Peak work rate in the incremental test (W) 91.8 (35.70)
Smoking history, n (%)
Ex-smoker 56 (62.9)
Current smoker 33 (37.1)
Number of pack years 44.5 (18.71)
Data are mean (SD) unless otherwise specified. BMI, body mass
index; SD Z standard deviation; FEV1 Z forced expiratory
volume in 1 s; FVC Z forced vital capacity.
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being re-classified as having mild COPD. The pre-treatment
exercise endurance time in the constant work rate test
averaged 459 s.
Efficacy
Exercise endurance time
For the primary efficacy variable, exercise endurance time
after 3 weeks of treatment, indacaterol 300 mg was signif-
icantly superior to placebo, with an LSM treatment differ-
ence of 111 s (95% CI: 27, 195, p Z 0.011) (Fig. 1). In
a subgroup analysis according to disease severity, theFigure 1 Exercise endurance time (seconds) on Day 1 and
after 3 weeks of treatment.endurance time after 3 weeks of treatment with indaca-
terol was significantly higher than placebo in patients with
FEV1 <50% predicted (difference of 229 s; 95% CI: 31, 426,
p Z 0.024) and was numerically higher than placebo in
patients with FEV1 50% predicted (difference of 85 s; 95%
CI: 10, 180, p Z 0.078). In a second subgroup analysis
according to smoking status at study entry, the endurance
time after 3 weeks with indacaterol was significantly higher
than with placebo in current smokers (difference of 161 s;
95% CI: 22, 299, pZ 0.023) and was numerically higher than
with placebo in ex-smokers (81 s; 95% CI: 25, 188,
p Z 0.132). On Day 1, indacaterol was also significantly
superior to placebo for exercise endurance time, with an
LSM treatment difference of 101 s (p < 0.001) (Fig. 1).
The most common reason for ceasing exercise in the
indacaterol treatment group was muscle fatigue (53% of
patients in the indacaterol group on Day 1 and 49% at Week
3); the most common reason in the placebo group was
dyspnea (57% on Day 1 and 53% at Week 3). A greater
proportion of patients with severe COPD discontinued due
to dyspnea in both groups, although again this was more
frequently quoted as the reason for discontinuation in the
placebo group (73% and 73% on Day 1 and Week 3) than the
indacaterol group (56% and 43%, respectively).
Other assessments during exercise
End-exercise IC was significantly higher with indacaterol
than with placebo both on Day 1 and after 3 weeks, with
LSM differences of 190 mL (p Z 0.04) and 280 mL
(p Z 0.002), respectively (Fig. 2). For Borg CR10 scale
outcomes, there were no significant differences at end-
exercise between indacaterol and placebo for either Borg
CR10 exertional dyspnea or Borg CR10 leg discomfort on Day
1 or after 3 weeks of treatment.
Resting spirometry assessments
Indacaterol treatment resulted in significant improvements
versus placebo in resting IC at 75 min post-dose on Day 1
(p < 0.001), and at 60 min predose (pZ 0.004) and 75 min
post-dose (pZ 0.001) after 3 weeks of treatment (Table 2).
The mean FEV1 and FVC values were also significantly
higher (p < 0.001) for indacaterol versus placebo at all of
these time points (Table 2).
Diary data and actigraphy
Indacaterol was associated with significant reductions in
the use of rescue medication compared with placebo over
the 3 weeks of treatment in terms of the number of puffs
used daily (LSM treatment difference of 1.2, p < 0.001),
the number of puffs used during daytime (LSM treatment
difference of 0.7, p < 0.001) and the number of puffs
used at nighttime (LSM treatment difference of 0.5,
pZ 0.003). Expressed as a change from baseline, there was
a 37% reduction from baseline in mean daily rescue use with
indacaterol compared with a 3% increase from baseline
with placebo. Use of indacaterol was also associated with
an increase in the percentage of days when patients did not
require rescue medication, with an indacateroleplacebo
difference of 14.4 percentage points (p Z 0.001).
Indacaterol treatment was associated with an overall
reduction in diary symptoms over the 3 weeks of treatment
(change from baseline in mean total symptom score of
Figure 2 End-exercise IC on Day 1 and after 3 weeks of
treatment.
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In terms of patients’ activity level assessed via actigraphy,
neither indacaterol nor placebo treatment had a significant
effect during the third week of treatment. The LSM esti-
mated average energy expenditure was 887 cal/day with
indacaterol compared to 891 cal/day with placebo
(p Z 0.879); the LSM physical activity duration was
43.3 min/day and 46.2 min/day, respectively (p Z 0.564).
Safety
The overall incidence of AEswas 22.9% (19/83) and 27.4% (23/
84) with indacaterol and placebo, respectively (Table 3), the
majority being mild or moderate in severity. The most
frequently reported AE with both treatments was nasophar-
yngitis (7.2 and 7.1% with indacaterol and placebo, respec-
tively).Of thepatientsdiscontinuingdue toAEs,a relationship
to study medication was suspected in one patient with inda-
caterol (erythema of the face, mild in severity) and three
patients with placebo. Three patients while on indacaterol
treatmentandonepatientonplaceboexperiencedSAEs;none
were suspected to be study drug related. No death was
reported during the study.
The only notable pre-exercise vital sign changes over the
3-week treatment period were observed in one patient,
who had a raised post-baseline diastolic blood pressure
measurement (114 mmHg) while on placebo and a low
measurement (40 mmHg) while on indacaterol. ClinicallyTable 2 Treatment difference between indacaterol and placeb
weeks of treatment (modified ITT population).
Outcome Indacateroleplacebo comparison
Day 1
75 min post-dose
IC (L) 0.20  0.038***
(0.13, 0.28)
FEV1 (L) 0.23  0.021***
(0.19, 0.27)
FVC (L) 0.30  0.044***
(0.21, 0.39)
Data are least squares means  standard error (95% CI). **p Z 0.004significant arrhythmias were noted in three patients; one
patient had ventricular premature complexes noted during
screening and at all visits during both treatment periods.
For the other two patients (one patient with ventricular
premature complexes and the other with unspecified
arrhythmia), the abnormalities occurred during screening
or placebo administration.Discussion
This study was primarily designed to assess the effect of
indacaterol 300 mg once-daily on exercise endurance time
in patients with moderate-to-severe COPD. Treatment with
indacaterol resulted in a significant improvement in exer-
cise endurance time, not only after 3 weeks but also after
a single-dose, with the indacateroleplacebo treatment
differences at both visits exceeding or meeting the
minimum clinically relevant improvement of 101 s specified
by Puente-Maestu and colleagues.17
To date, studies have been conducted to assess the
effect of bronchodilators on exercise capacity using either
constant work rate or incremental testing protocols. The
constant work rate cycle ergometer test was selected in
this study, as the protocol has been shown to be reliable
and sensitive to detect patients’ response to bronchodilator
interventions in COPD.14,18,19 Furthermore, the change in
exercise capacity objectively measured in patients with
COPD using a symptom-limited cycle ergometry test has
been shown to correlate with changes in their health
status.20 The overall improvement in exercise capacity
achieved with indacaterol in the current study could be one
of the explanations for the improved health status
(assessed using the Saint George’s Respiratory Question-
naire) seen with indacaterol in long-term studies.8,9
Indacaterol also showed a significant improvement in
end-exercise IC after 3 weeks of treatment, with a differ-
ence from placebo of 280 mL. IC, being an important indi-
cator of lung hyperinflation, has been shown to be more
closely related to exercise tolerance than other spirometric
indices, including FEV1 and FVC.
2 Reduced hyperinflation,
may therefore be one of the reasons for improved exercise
performance achieved following indacaterol treatment. In
the present study, the Borg CR10 scale outcomes e exer-
tional dyspnea and leg discomfort e were assessed at the
symptom-limited end of exercise. Although the exerciseo groups in resting spirometry outcomes on Day 1 and after 3
After 3 weeks
60 min predose 75 min post-dose
0.14  0.048** 0.17  0.050***
(0.04, 0.23) (0.07, 0.27)
0.20  0.030*** 0.25  0.032***
(0.14, 0.26) (0.19, 0.31)
0.22  0.051*** 0.26  0.057***
(0.12, 0.32) (0.15, 0.38)
; ***p  0.001.
Table 3 Most frequent AEs (2% in any treatment group).
AEs Indacaterol 300 mg
N Z 83, n (%)
Placebo
N Z 84, n (%)
Patients with any AE(s) 19 (22.9) 23 (27.4)
Nasopharyngitis 6 (7.2) 6 (7.1)
Bronchitis 2 (2.4) 0
COPD including exacerbations 2 (2.4) 5 (6.0)
Cough 2 (2.4) 2 (2.4)
Upper respiratory tract infection 2 (2.4) 0
Upper respiratory tract infection bacterial 0 2 (2.4)
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indacaterol than while receiving placebo, there were no
statistically significant differences between treatments in
Borg CR10 scores at the end of exercise. The results indi-
cate that when patients received indacaterol they were
able to endure constant work rate for longer before expe-
riencing intolerable levels of exertional dyspnea and leg
discomfort. These results are in line with those observed in
a previous exercise endurance study, in which there were
no statistically significant differences between tiotropium
and placebo in terms of Borg exertional dyspnea assessed at
the end of exercise, yet tiotropium was associated with
a significant increase in exercise endurance time.16 To the
best of our knowledge, no studies to date have demon-
strated that pharmacological interventions alone can
improve daily activity levels in patients with COPD e and in
the current study, patients’ activity level measured using
an actigraphy device showed no significant treatment
effects. This finding could possibly be attributed to the lack
of pulmonary rehabilitation in this study, since other
studies have shown that daily activity levels are most
effectively increased when (as recommended by treatment
guidelines) bronchodilator pharmacotherapy is combined
with pulmonary rehabilitation.21,22 However, the study was
not powered to examine changes in activity levels; it would
be interesting to examine the effect of indacaterol on
activity levels in a larger, longer study.
Indacaterol provided significant improvements in resting
IC (indacateroleplacebo differences of 140e200 mL). While
these treatmenteplacebo differences were less than those
observed in the previous tiotropium study (tio-
tropiumeplacebo differences of 210e250 mL),16 the tio-
tropium study recruited a larger proportion of patients with
severe COPD. In contrast, approximately 76% of patients in
the current study had moderate disease. Given differences
in design between these two studies (parallel versus
crossover), results should be compared with caution;
however, patients with more severe disease are known to
exhibit more air trapping than those with more moderate
COPD,23 and as a consequence their exercise capacity is
more likely to be limited by their ventilatory response. In
such patients, a bronchodilator such as indacaterol could
be predicted to provide a greater increase in exercise
capacity than in patients with more moderate disease,
whose exercise capacity is likely to be less limited by their
lung function. Indeed, the improvement in exercise
endurance time in the current study was particularly
apparent in patients with more severe COPD (FEV1 <50%
predicted), who gained more benefit from indacaterol thandid patients with more moderate COPD (FEV1 50% pre-
dicted). Indacaterol also provided improvements in other
resting lung function assessments, including FEV1, and FVC.
Similar improvements in FEV1 and FVC have been observed
with indacaterol in previous studies.8e10
No conclusions can be drawn about the dynamic shift of
IC during exercise with indacaterol, as this would require an
evaluation of lung function (and potentially Borg CR10
scores) at intervals throughout the exercise test. The
inclusion of such evaluations would be valuable inclusions
in future studies of indacaterol e at least in part as this
would permit calculation of isotime responses. The inda-
caterol dose tested in the present study is the higher of the
two doses currently approved (150 mg and 300 mg). Although
the bronchodilator efficacy of the 150 mg dose has been
demonstrated in a large number of studies,9,10,24 none of
these included assessments of exercise capacity. As
a consequence, it is difficult to speculate on the compar-
ative efficacy of these two doses in terms of the efficacy
parameters reported here.
There were no clinically relevant differences between
indacaterol and placebo regarding AEs incidence and
severity. The numbers of patients with SAEs, and that
permanently discontinued study drug were very low; no
deaths were reported during the study.
Conclusion
In conclusion, indacaterol provided clinically meaningful
improvements in exercise endurance with sustained
reductions in lung hyperinflation both at rest and at the end
of exercise.
Acknowledgments
The authors thank the patients who took part and the staff
at the participating clinical centers. This study was funded
by Novartis Pharma AG, Basel, Switzerland. The authors
would like to thank Lakshmi Kasthurirangan professional
medical writer (Novartis) and David Young (Novartis) for
their assistance in preparing the manuscript.Conflict of interest
Denis E O’Donnell has served on advisory boards for Boeh-
ringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed and
Pfizer; has received lecture fees from AstraZeneca,
1036 D.E. O’Donnell et al.Boehringer Ingelheim, GlaxoSmithKline and Pfizer; and has
received industry-sponsored research grants from AstraZe-
neca, Boehringer Ingelheim, GlaxoSmithKline, Merck Frosst
Canada, Novartis and Pfizer. Richard Casaburi has served as
consultant to advisory boards for Boehringer Ingelheim,
Pfizer, Forest, AstraZeneca, Theratechnologies, Medtronics
and Novartis. Los Angeles Biomedical Research Institute
participated as an investigational site in this study under
contractwithNovartis.Walter Vincken has beenamember of
advisory boards for Altana/Nycomed, AstraZeneca, Boeh-
ringer Ingelheim/Pfizer, GlaxoSmithKline, Meda, MSD,
Novartis and UCB; has given lectures for these pharmaceu-
tical companies as well as for Abbott and Zambon; and has
received research or educational grants from AstraZeneca,
Boehringer Ingelheim/Pfizer, GlaxoSmithKline and Novartis.
Luis Puente-Maestu has received fees for lectures by Glax-
oSmithKline, ASTRA and Admirall-Prodes pharma and MED-
GRAPHICS (an exercise systems company) andwas sponsored
to attend to Respiratorymeetings by Astra, GlaxoSmithKline,
Esteve, Pfizer, Chiesi and Admirall. David Lawrence and
Benjamin Kramer are employees of the study sponsor,
Novartis PharmaAG. James Swaleswas employed byNovartis
at the time of study conduct. All authors contributed to the
development of the manuscript, and approved the decision
to submit the manuscript for publication.
References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. Updated 2010. At,
http://www.goldcopd.org (accessed: 11 March 2011).
2. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of
improvement in exercise performance after anticholinergic
therapy in COPD. Am J Respir Crit Care Med 1999;160:
542e9.
3. O’Donnell DE, Webb KA. The major limitation to exercise
performance in COPD is dynamic hyperinflation. J Appl Physiol
2008;105:753e5.
4. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M,
Pe´rez-Izquierdo J, et al. Impact of changes in physical activity
on health-related quality of life among patients with chronic
obstructive pulmonary disease. Eur Respir J 2010;36:292e300.
5. Neder JA, Fuld JP, Overend T, Thirlwell J, Carter R,
Stevenson R, et al. Effects of formoterol on exercise tolerance
in severely disabled patients with COPD. Respir Med 2007;101:
2056e64.
6. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC,
Richter K, et al. Improvements in symptom-limited exercise
performance over 8 h with once-daily tiotropium in patients
with COPD. Chest 2005;128:1168e78.
7. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-
agonists in development for asthma and chronic obstructive
pulmonary disease. Expert Opin Investig Drugs 2005;14:
775e83.
8. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D,
et al. Efficacy of a new once-daily long-acting inhaled b2-
agonist indacaterol versus twice-daily formoterol in COPD.
Thorax 2010;65:473e9.9. Donohue JF, Fogarty C, Lo¨tvall J, Mahler DA, Worth H,
Yorganciolu A, et al. Once-daily bronchodilators for chronic
obstructive pulmonary disease: indacaterol versus tiotropium.
Am J Respir Crit Care Med 2010;182:155e62.
10. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al.
Efficacy and safety of indacaterol 150 mg once-daily in COPD:
a double-blind, randomised, 12-week study. BMC Pulm Med
2010;10:11.
11. Clinical Trials.gov. NCT00620022. US National Institutes of
Health. The effect of indacaterol on exercise endurance in
patientswithmoderate to severe chronic obstructive pulmonary
disease, http://clinicaltrials.gov/ct2/show/NCT00620022?
termZCQAB149B2311&rankZ1 (accessed: 11 March 2011).
12. Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. 2005 Revision. At:
http://www.goldcopd.com (accessed: 11 March 2011).
13. Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC. Lung volumes and forced ventilatory flows. Eur
Respir J 1993;6(Suppl 16):5e40. Report Working Party Standard-
ization of LungFunctionTests, EuropeanCommunity for Steel and
Coal. Official Statement of the European Respiratory Society.
14. American Thoracic Society/American College of Chest Physi-
cians. ATS/ACCP statement on cardiopulmonary exercise
testing. Am J Respir Crit Care Med 2003;167:211e77.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R,
Coates A, et al. Standardisation of spirometry. Eur Respir J
2005;26:319e38.
16. O’Donnell DE, Flu¨ge T, Gerken F, Hamilton A, Webb K,
Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation,
dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;
23:832e40.
17. Puente-Maestu L, Villar F, de Miguel J, Stringer WW, Sanz P,
Sanz ML, et al. Clinical relevance of constant power exercise
duration changes in COPD. Eur Respir J 2009;34:340e5.
18. O’Donnell DE, Travers J, Webb KA, He Z, Lam Y-M, Hamilton A,
et al. Reliability of ventilatory parameters during cycle ergo-
metry in multicenter trials in COPD. Eur Respir J 2009;34:
866e74.
19. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms,
lung hyperinflation, and endurance during exercise in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
1998;158:1557e65.
20. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M.
Longitudinal deteriorations in patient reported outcomes in
patients with COPD. Respir Med 2007;101(1):146e53.
21. Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in
self-reported exercise participation with the combination of
tiotropium and rehabilitative exercise training in COPD
patients. Int J COPD 2008;3(1):127e36.
22. Pasqua F, Biscione G, Crigna G, Auciello L, Cazzola M.
Combining triple therapy and pulmonary rehabilitation in
patients with advanced COPD: a pilot study. Resp Med 2010;
104:412e7.
23. Vogiatzis I, Stratakos G, Athanasopoulos D, Georgiadou O,
Golemati S, Koutsoukou A, et al. Chest wall volume regulation
during exercise in COPD patients with GOLD stages II to IV. Eur
Respir J 2008;32:42e52.
24. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C,
et al. Once daily indacaterol versus twice-daily salmeterol for
COPD: a placebo-controlled comparison. Eur Resp J 2011;37:
273e9.
